000			02890nam a22003377a 4500
008			171110s20172017 xxu||||| |||| 00| 0 eng d
022			_a2052-4897
040			_aOvid MEDLINE(R)
099			_a29081977
245			_aStatin use and risk of developing diabetes: results from the Diabetes Prevention Program.
251			_aBMJ Open Diabetes Research & Care. 5(1):e000438, 2017
252			_aBMJ open diabetes res. care. 5(1):e000438, 2017
253			_aBMJ open diabetes research & care
260			_c2017
260			_fFY2018
266			_d2017-11-10
520			_aCONCLUSIONS: In this population at high risk for diabetes, we observed significantly higher rates of diabetes with statin therapy in all three treatment groups. Confounding by indication for statin use does not appear to explain this relationship. The effect of statins to increase diabetes risk appears to extend to populations at high risk for diabetes.
520			_aOBJECTIVE: Several clinical trials of cardiovascular disease prevention with statins have reported increased risk of type 2 diabetes (T2DM) with statin therapy. However, participants in these studies were at relatively low risk for diabetes. Further, diabetes was often based on self-report and was not the primary outcome. It is unknown whether statins similarly modify diabetes risk in higher risk populations.
520			_aRESEARCH DESIGN AND METHODS: During the Diabetes Prevention Program Outcomes Study (n=3234), the long-term follow-up to a randomized clinical trial of interventions to prevent T2DM, incident diabetes was assessed by annual 75g oral glucose tolerance testing and semiannual fasting glucose. Lipid profile was measured annually, with statin treatment determined by a participant's own physician outside of the protocol. Statin use was assessed at baseline and semiannual visits.
520			_aRESULTS: At 10years, the cumulative incidence of statin initiation prior to diabetes diagnosis was 33%-37%among the randomized treatment groups (p=0.36). Statin use was associated with greater diabetes risk irrespective of treatment group, with pooled HR (95%CI) for incident diabetes of 1.36 (1.17 to 1.58). This risk was not materially altered by adjustment for baseline diabetes risk factors and potential confounders related to indications for statin therapy.
520			_aTRIAL REGISTRATION NUMBER: NCT00038727; Results.
546			_aEnglish
650			_aPubMed-not-MEDLINE -- Not indexed
651			_aMedStar Health Research Institute
651			_aMedStar Washington Hospital Center
657			_aJournal Article
700			_aRatner, Robert E
790			_aBarrett-Connor E, Crandall JP, Foo S, Goldberg RB, Mather K, Rajpathak SN, Ratner R, Temprosa M, Watson K
856			_uhttps://dx.doi.org/10.1136/bmjdrc-2017-000438 _zhttps://dx.doi.org/10.1136/bmjdrc-2017-000438
942			_cART _dArticle
999			_c2819 _d2819